Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Receivables (2021 - 2025)

Zymeworks' Receivables history spans 3 years, with the latest figure at $67.3 million for Q3 2023.

  • For Q3 2023, Receivables rose 591.54% year-over-year to $67.3 million; the TTM value through Sep 2023 reached $67.3 million, up 591.54%, while the annual FY2022 figure was $36.4 million, 133.12% up from the prior year.
  • Receivables for Q3 2023 was $67.3 million at Zymeworks, up from $48.8 million in the prior quarter.
  • Across five years, Receivables topped out at $69.9 million in Q1 2023 and bottomed at $9.7 million in Q3 2022.
  • The 3-year median for Receivables is $42.6 million (2022), against an average of $41.3 million.
  • The largest annual shift saw Receivables surged 133.12% in 2022 before it skyrocketed 591.54% in 2023.
  • A 3-year view of Receivables shows it stood at $15.6 million in 2021, then soared by 133.12% to $36.4 million in 2022, then skyrocketed by 84.82% to $67.3 million in 2023.
  • Per Business Quant, the three most recent readings for ZYME's Receivables are $67.3 million (Q3 2023), $48.8 million (Q2 2023), and $69.9 million (Q1 2023).